Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis
Brief Summary: This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.


Options:
A: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group 1-6d Combined: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to VX-661, Drug: Placebo matched to ivacaftor | Arm Label: Group 1: VX-661 10 mg qd; Type: EXPERIMENTAL; Interventions: Drug: VX-661 | Arm Label: Group 2a: VX-661 30 mg qd; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Placebo matched to ivacaftor | Arm Label: Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 3a: VX-661 100 mg qd; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Placebo matched to ivacaftor | Arm Label: Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 5a: VX-661 150 mg qd; Type: EXPERIMENTAL; Interventions: Drug: VX-661 | Arm Label: Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Arm Label: Group 7: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivacaftor, Drug: Placebo matched to VX-661 | Arm Label: Group 7: VX-661 100 mg qd; Type: EXPERIMENTAL; Interventions: Drug: VX-661, Drug: Ivacaftor | Intervention Type: DRUG; Name: VX-661; Assigned to Arm(s): Group 1: VX-661 10 mg qd, Group 2a: VX-661 30 mg qd, Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h, Group 3a: VX-661 100 mg qd, Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h, Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h, Group 5a: VX-661 150 mg qd, Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h, Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h, Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h, Group 7: VX-661 100 mg qd | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h, Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h, Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h, Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h, Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h, Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h, Group 7: Placebo, Group 7: VX-661 100 mg qd | Intervention Type: DRUG; Name: Placebo matched to VX-661; Assigned to Arm(s): Group 1-6d Combined: Placebo, Group 7: Placebo | Intervention Type: DRUG; Name: Placebo matched to ivacaftor; Assigned to Arm(s): Group 1-6d Combined: Placebo, Group 2a: VX-661 30 mg qd, Group 3a: VX-661 100 mg qd
C: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
D: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A